Scrip RSS Feedhttps://insights.citeline.comThe Latest News & Analysis from ScripThu, 01 Oct 2026 22:14:01 +0000en1hourly1 https://insights.citeline.com/scrip/business/earnings/scrips-guide-to-october-2026-esmo-q3s-and-novel-anti-infectives-approvals-COD2U3DRCJBE7LOMAA4SXLGD4E/<![CDATA[Scrip’s Guide To October 2026: ESMO, Q3s and Novel Anti-Infectives Approvals]]>premium

      
]]> https://feeds.feedblitz.com/~/970847021/0/scrip~Scrip%e2%80%99s-Guide-To-October-ESMO-Qs-and-Novel-AntiInfectives-Approvals/https://insights.citeline.com/scrip/business/earnings/scrips-guide-to-october-2026-esmo-q3s-and-novel-anti-infectives-approvals-COD2U3DRCJBE7LOMAA4SXLGD4E/
      
]]> Thu, 01 Oct 2026 11:17:07 +0000 https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/lilly-reinforces-its-lead-in-obesity-but-theres-still-room-for-new-arrivals-MBWHTE2YRNC77O53IUXW7CRTEA/<![CDATA[Lilly Reinforces Its Lead In Obesity, But There’s Still Room For New Arrivals]]>premium

      
]]> https://feeds.feedblitz.com/~/970868096/0/scrip~Lilly-Reinforces-Its-Lead-In-Obesity-But-There%e2%80%99s-Still-Room-For-New-Arrivals/https://insights.citeline.com/scrip/therapeutic-category/alimentary-metabolic/obesity/lilly-reinforces-its-lead-in-obesity-but-theres-still-room-for-new-arrivals-MBWHTE2YRNC77O53IUXW7CRTEA/
      
]]> Thu, 01 Oct 2026 16:41:54 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/taiho-draws-from-hypomethylating-agent-experience-in-astx030-program-NOPV5X45UNDN3AJD34BXVPQ6F4/<![CDATA[Taiho Draws From Hypomethylating Agent Experience In ASTX030 Program ]]>premium

      
]]> https://feeds.feedblitz.com/~/970874822/0/scrip~Taiho-Draws-From-Hypomethylating-Agent-Experience-In-ASTX-Program/https://insights.citeline.com/scrip/r-and-d/clinical-trials/taiho-draws-from-hypomethylating-agent-experience-in-astx030-program-NOPV5X45UNDN3AJD34BXVPQ6F4/
      
]]> Thu, 01 Oct 2026 20:27:39 +0000 https://insights.citeline.com/scrip/business/deals/deal-watch/deal-watch-abbvie-looks-to-iambic-valkai-for-ai-discovery-and-development-help-KW6TY23O6NBRJHTXSQJZ72PMF4/<![CDATA[Deal Watch: AbbVie Looks To Iambic, Valkai For AI Discovery And Development Help]]>premium

      
]]> https://feeds.feedblitz.com/~/970874819/0/scrip~Deal-Watch-AbbVie-Looks-To-Iambic-Valkai-For-AI-Discovery-And-Development-Help/https://insights.citeline.com/scrip/business/deals/deal-watch/deal-watch-abbvie-looks-to-iambic-valkai-for-ai-discovery-and-development-help-KW6TY23O6NBRJHTXSQJZ72PMF4/
      
]]> Thu, 01 Oct 2026 20:42:09 +0000 https://insights.citeline.com/scrip/business/deals/sanofi-and-regeneron-rekindle-their-alliance-but-will-magic-strike-again-XIMXX2FTL5FZHPA66WMRLV2BCE/<![CDATA[Sanofi And Regeneron Rekindle Their Alliance, But Will Magic Strike Again? ]]>premium

      
]]> https://feeds.feedblitz.com/~/970876151/0/scrip~Sanofi-And-Regeneron-Rekindle-Their-Alliance-But-Will-Magic-Strike-Again/https://insights.citeline.com/scrip/business/deals/sanofi-and-regeneron-rekindle-their-alliance-but-will-magic-strike-again-XIMXX2FTL5FZHPA66WMRLV2BCE/
      
]]> Thu, 01 Oct 2026 21:37:15 +0000 https://insights.citeline.com/scrip/business/strategy/minoryx-eyes-pipeline-in-a-product-prospects-for-nezglyal-after-eu-okay-HDBE474ZJNAM7OABDAGKK6ZHQ4/<![CDATA[Minoryx Eyes Pipeline-In-A-Product Prospects For Nezglyal After EU Okay]]>premium

      
]]> https://feeds.feedblitz.com/~/970806023/0/scrip~Minoryx-Eyes-PipelineInAProduct-Prospects-For-Nezglyal-After-EU-Okay/https://insights.citeline.com/scrip/business/strategy/minoryx-eyes-pipeline-in-a-product-prospects-for-nezglyal-after-eu-okay-HDBE474ZJNAM7OABDAGKK6ZHQ4/
      
]]> Wed, 30 Sep 2026 13:25:06 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/pfizers-phase-ii-atopic-dermatitis-data-push-tilrekimig-into-pivotal-ad-asthma-trials-KDJR2KQ4CZFCBFKLIMLADRSHAA/<![CDATA[Pfizer’s Phase II Atopic Dermatitis Data Push Tilrekimig Into Pivotal AD, Asthma Trials]]>premium

      
]]> https://feeds.feedblitz.com/~/970839326/0/scrip~Pfizer%e2%80%99s-Phase-II-Atopic-Dermatitis-Data-Push-Tilrekimig-Into-Pivotal-AD-Asthma-Trials/https://insights.citeline.com/scrip/r-and-d/clinical-trials/pfizers-phase-ii-atopic-dermatitis-data-push-tilrekimig-into-pivotal-ad-asthma-trials-KDJR2KQ4CZFCBFKLIMLADRSHAA/
      
]]> Thu, 01 Oct 2026 06:35:00 +0000 https://insights.citeline.com/scrip/business/deals/regeneron-sanofi-extend-dupixent-playbook-with-four-next-gen-immunology-antibodies-MIRGDUJ5E5GBVP3GMORTBEYKZI/<![CDATA[Regeneron, Sanofi Extend Dupixent Playbook With Four Next-Gen Immunology Antibodies]]>premium

      
]]> https://feeds.feedblitz.com/~/970842575/0/scrip~Regeneron-Sanofi-Extend-Dupixent-Playbook-With-Four-NextGen-Immunology-Antibodies/https://insights.citeline.com/scrip/business/deals/regeneron-sanofi-extend-dupixent-playbook-with-four-next-gen-immunology-antibodies-MIRGDUJ5E5GBVP3GMORTBEYKZI/
      
]]> Thu, 01 Oct 2026 08:10:42 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/abbvie-has-eye-on-dupixent-and-ebglyss-as-it-readies-zumilokibart-for-phase-iii-LSS7DWK7OBHQ3E2NPQP7UNKWDY/<![CDATA[AbbVie Has Eye On Dupixent And Ebglyss As It Readies Zumilokibart For Phase III ]]>premium

      
]]> https://feeds.feedblitz.com/~/970827539/0/scrip~AbbVie-Has-Eye-On-Dupixent-And-Ebglyss-As-It-Readies-Zumilokibart-For-Phase-III/https://insights.citeline.com/scrip/r-and-d/clinical-trials/abbvie-has-eye-on-dupixent-and-ebglyss-as-it-readies-zumilokibart-for-phase-iii-LSS7DWK7OBHQ3E2NPQP7UNKWDY/
      
]]> Wed, 30 Sep 2026 22:32:14 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/lillys-amylin-combo-could-be-best-weight-loss-drug-yet-WMTP4CBW4VDPTESL2FRAIC4LSU/<![CDATA[Lilly’s Amylin Combo Could Be Best Weight Loss Drug Yet]]>premium

      
]]> https://feeds.feedblitz.com/~/970814801/0/scrip~Lilly%e2%80%99s-Amylin-Combo-Could-Be-Best-Weight-Loss-Drug-Yet/https://insights.citeline.com/scrip/r-and-d/clinical-trials/lillys-amylin-combo-could-be-best-weight-loss-drug-yet-WMTP4CBW4VDPTESL2FRAIC4LSU/
      
]]> Wed, 30 Sep 2026 14:15:29 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/vandas-hetlioz-expansion-push-faces-a-new-test-after-fda-setbacks-ESJZPOA76FFBLIDBQQWRNO4W4U/<![CDATA[Vanda’s Hetlioz Expansion Push Faces A New Test After FDA Setbacks]]>premium

      
]]> https://feeds.feedblitz.com/~/970818548/0/scrip~Vanda%e2%80%99s-Hetlioz-Expansion-Push-Faces-A-New-Test-After-FDA-Setbacks/https://insights.citeline.com/scrip/r-and-d/clinical-trials/vandas-hetlioz-expansion-push-faces-a-new-test-after-fda-setbacks-ESJZPOA76FFBLIDBQQWRNO4W4U/
      
]]> Wed, 30 Sep 2026 15:48:02 +0000 https://insights.citeline.com/scrip/therapeutic-category/immunological/merck-cos-phase-ii-for-tulisokibart-is-a-first-for-tl1a-in-dermatology-DMO5U3ZS7BED7LX7JARVLRE27Q/<![CDATA[Merck & Co.’s Phase II For Tulisokibart Is A First For TL1A In Dermatology ]]>premium

      
]]> https://feeds.feedblitz.com/~/970822904/0/scrip~Merck-Co%e2%80%99s-Phase-II-For-Tulisokibart-Is-A-First-For-TLA-In-Dermatology/https://insights.citeline.com/scrip/therapeutic-category/immunological/merck-cos-phase-ii-for-tulisokibart-is-a-first-for-tl1a-in-dermatology-DMO5U3ZS7BED7LX7JARVLRE27Q/
      
]]> Wed, 30 Sep 2026 18:44:56 +0000 https://insights.citeline.com/scrip/business/strategy/lillys-ebglyss-to-take-on-dupixent-in-hand-foot-atopic-dermatitis-5ZF3OJATNZCN3PCCW54RFNQDOY/<![CDATA[Lilly’s Ebglyss To Take On Dupixent In Hand, Foot Atopic Dermatitis]]>premium

      
]]> https://feeds.feedblitz.com/~/970826315/0/scrip~Lilly%e2%80%99s-Ebglyss-To-Take-On-Dupixent-In-Hand-Foot-Atopic-Dermatitis/https://insights.citeline.com/scrip/business/strategy/lillys-ebglyss-to-take-on-dupixent-in-hand-foot-atopic-dermatitis-5ZF3OJATNZCN3PCCW54RFNQDOY/
      
]]> Wed, 30 Sep 2026 21:11:10 +0000 https://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bms-keeps-its-cardiomyopathy-lead-for-now-with-camzyos-pediatric-indication-GN6IB5RGVFBCRMMBQAQD4XNS5M/<![CDATA[BMS Keeps Its Cardiomyopathy Lead, For Now, With Camzyos Pediatric Indication]]>premium

      
]]> https://feeds.feedblitz.com/~/970827017/0/scrip~BMS-Keeps-Its-Cardiomyopathy-Lead-For-Now-With-Camzyos-Pediatric-Indication/https://insights.citeline.com/scrip/therapeutic-category/cardiovascular/bms-keeps-its-cardiomyopathy-lead-for-now-with-camzyos-pediatric-indication-GN6IB5RGVFBCRMMBQAQD4XNS5M/
      
]]> Wed, 30 Sep 2026 21:39:19 +0000 https://insights.citeline.com/scrip/leadership/quotables-pharma-leaders-on-the-months-hot-topics-6PQHOHFW3JFFVNFYKNLUQGIHDU/<![CDATA[Quotables: Pharma Leaders On The Month’s Hot Topics]]>free

      
]]> https://feeds.feedblitz.com/~/970799843/0/scrip~Quotables-Pharma-Leaders-On-The-Month%e2%80%99s-Hot-Topics/https://insights.citeline.com/scrip/leadership/quotables-pharma-leaders-on-the-months-hot-topics-6PQHOHFW3JFFVNFYKNLUQGIHDU/
      
]]> Wed, 30 Sep 2026 08:55:33 +0000 https://insights.citeline.com/scrip/business/deals/astrazenecas-2bn-summit-deal-puts-emerging-pd-1vegf-adc-race-in-focus-766IVXIOOZACPEEVS7Y542G4LE/<![CDATA[AstraZeneca’s $2bn Summit Deal Puts Emerging PD-1/VEGF-ADC Race In Focus]]>premium

      
]]> https://feeds.feedblitz.com/~/970776215/0/scrip~AstraZeneca%e2%80%99s-bn-Summit-Deal-Puts-Emerging-PDVEGFADC-Race-In-Focus/https://insights.citeline.com/scrip/business/deals/astrazenecas-2bn-summit-deal-puts-emerging-pd-1vegf-adc-race-in-focus-766IVXIOOZACPEEVS7Y542G4LE/
      
]]> Tue, 29 Sep 2026 16:42:02 +0000 https://insights.citeline.com/scrip/focus-on-asia/india/gsks-zejula-faces-patent-challenge-by-natco-in-india-HG43RSG7YFH6XDS7ICBFT7345M/<![CDATA[GSK’s Zejula Faces Patent Challenge By Natco In India]]>premium

      
]]> https://feeds.feedblitz.com/~/970794746/0/scrip~GSK%e2%80%99s-Zejula-Faces-Patent-Challenge-By-Natco-In-India/https://insights.citeline.com/scrip/focus-on-asia/india/gsks-zejula-faces-patent-challenge-by-natco-in-india-HG43RSG7YFH6XDS7ICBFT7345M/
      
]]> Wed, 30 Sep 2026 05:57:38 +0000 https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgen-readies-daxdilimab-for-phase-iii-in-discoid-lupus-after-mid-stage-trial-O7Z3KNGGKVCK5FUZYCMDYG3FNQ/<![CDATA[Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial]]>premium

      
]]> https://feeds.feedblitz.com/~/970793177/0/scrip~Amgen-Readies-Daxdilimab-For-Phase-III-In-Discoid-Lupus-After-MidStage-Trial/https://insights.citeline.com/scrip/r-and-d/clinical-trials/amgen-readies-daxdilimab-for-phase-iii-in-discoid-lupus-after-mid-stage-trial-O7Z3KNGGKVCK5FUZYCMDYG3FNQ/
      
]]> Wed, 30 Sep 2026 05:05:00 +0000 https://insights.citeline.com/scrip/business/deals/tanabe-il-33-antibody-buy-builds-tolerance-pipeline-ZEDIOKFGX5GDDHTIHXZ3IB4PLA/<![CDATA[Tanabe IL-33 Antibody Buy Builds Tolerance Pipeline]]>premium

      
]]> https://feeds.feedblitz.com/~/970742714/0/scrip~Tanabe-IL-Antibody-Buy-Builds-Tolerance-Pipeline/https://insights.citeline.com/scrip/business/deals/tanabe-il-33-antibody-buy-builds-tolerance-pipeline-ZEDIOKFGX5GDDHTIHXZ3IB4PLA/
      
]]> Tue, 29 Sep 2026 07:23:40 +0000 https://insights.citeline.com/scrip/therapeutic-category/sensory/ophthalmology/the-race-to-shake-up-the-wet-amd-market-intensifies-OEXR47NL5NF35CXKKIM274RJK4/<![CDATA[The Race To Shake Up The Wet-AMD Market Intensifies ]]>premium

      
]]> https://feeds.feedblitz.com/~/970783301/0/scrip~The-Race-To-Shake-Up-The-WetAMD-Market-Intensifies/https://insights.citeline.com/scrip/therapeutic-category/sensory/ophthalmology/the-race-to-shake-up-the-wet-amd-market-intensifies-OEXR47NL5NF35CXKKIM274RJK4/
      
]]> Tue, 29 Sep 2026 21:19:57 +0000 https://insights.citeline.com/scrip/business/strategy/roches-pipeline-reset-puts-2027-in-focus-as-key-launches-readouts-loom-3T2SYNLCMFHLDJHTQNST6F72DY/<![CDATA[Roche’s Pipeline Reset Puts 2027 In Focus As Key Launches, Readouts Loom]]>premium

      
]]> https://feeds.feedblitz.com/~/970767533/0/scrip~Roche%e2%80%99s-Pipeline-Reset-Puts-In-Focus-As-Key-Launches-Readouts-Loom/https://insights.citeline.com/scrip/business/strategy/roches-pipeline-reset-puts-2027-in-focus-as-key-launches-readouts-loom-3T2SYNLCMFHLDJHTQNST6F72DY/
      
]]> Tue, 29 Sep 2026 14:13:56 +0000 https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/immix-to-target-car-t-centers-in-nxc-201-commercialization-push-after-positive-results-6EYRTE7UYVF4ZBMNCUKSFOKSHU/<![CDATA[Immix To Target CAR-T Centers In NXC-201 Commercialization Push After Positive Results]]>premium

      
]]> https://feeds.feedblitz.com/~/970782113/0/scrip~Immix-To-Target-CART-Centers-In-NXC-Commercialization-Push-After-Positive-Results/https://insights.citeline.com/scrip/advanced-therapies/cell-therapies/immix-to-target-car-t-centers-in-nxc-201-commercialization-push-after-positive-results-6EYRTE7UYVF4ZBMNCUKSFOKSHU/
      
]]> Tue, 29 Sep 2026 20:32:41 +0000 https://insights.citeline.com/scrip/business/deals/novo-expands-into-oral-weekly-obesity-therapy-through-hengrui-deal-2IG77ANIKJHK3KEOMD7WGSJEBQ/<![CDATA[Novo Expands Into Oral Weekly Obesity Therapy Through Hengrui Deal]]>premium

      
]]> https://feeds.feedblitz.com/~/970744616/0/scrip~Novo-Expands-Into-Oral-Weekly-Obesity-Therapy-Through-Hengrui-Deal/https://insights.citeline.com/scrip/business/deals/novo-expands-into-oral-weekly-obesity-therapy-through-hengrui-deal-2IG77ANIKJHK3KEOMD7WGSJEBQ/
      
]]> Tue, 29 Sep 2026 08:11:11 +0000 https://insights.citeline.com/scrip/business/financing/breye-secures-cash-boost-for-diabetes-driven-blindness-pill-WLJMA343PVCFJJ5KHAZLM7IGY4/<![CDATA[Breye Secures Cash Boost For Diabetes-Driven Blindness Pill]]>premium

      
]]> https://feeds.feedblitz.com/~/970742711/0/scrip~Breye-Secures-Cash-Boost-For-DiabetesDriven-Blindness-Pill/https://insights.citeline.com/scrip/business/financing/breye-secures-cash-boost-for-diabetes-driven-blindness-pill-WLJMA343PVCFJJ5KHAZLM7IGY4/
      
]]> Tue, 29 Sep 2026 07:31:10 +0000 https://insights.citeline.com/scrip/r-and-d/emugrobart-down-in-obesity-but-not-out-for-sma-TEE33RICJFCDDDWUHXPZC7LGEM/<![CDATA[Emugrobart Down In Obesity But Not Out For SMA]]>premium

      
]]> https://feeds.feedblitz.com/~/970729583/0/scrip~Emugrobart-Down-In-Obesity-But-Not-Out-For-SMA/https://insights.citeline.com/scrip/r-and-d/emugrobart-down-in-obesity-but-not-out-for-sma-TEE33RICJFCDDDWUHXPZC7LGEM/
      
]]> Tue, 29 Sep 2026 03:29:33 +0000